Fu Yu Corporation Limited (SG:F13) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Fu Yu Corporation Limited showcased a strong first quarter in 2024, with its revenue soaring to S$78.9 million, more than doubling from the previous year, driven by significant growth in its supply chain management business. The company also marked a financial turnaround, posting a net profit of S$5,200, rebounding from a net loss in the same quarter of the previous year. Additionally, Fu Yu secured lucrative new projects in the biomedical and export tooling sectors, including an exclusive supplier agreement with a Singapore-based medical device manufacturer.
For further insights into SG:F13 stock, check out TipRanks’ Stock Analysis page.
